Clinical utility of early improvement to predict response or remission in acute @entity162 : focus on @entity1037 and XXXX .

@entity1 @entity162 @entity716 @entity1037 @entity1090
OBJECTIVE: To evaluate early improvement associated with atypical antipsychotic treatment as a predictor of later response or remission among @entity1 experiencing an acute @entity162 or mixed episode without @entity716 features. METHOD: A post hoc analysis was performed on data from a 3-week, randomized, double-blind clinical trial of @entity1037 (N = 147) or @entity1090 (N = 127) to treat inpatients aged 18-70 years meeting DSM-IV criteria for @entity162 . Early improvement, measured as percent change (>=  25% and >=  50% cut points) in the Young Mania Rating Scale (YMRS) total score, was assessed after 2 days and 1 week of treatment. Receiver operating characteristic curves, sensitivity and specificity, and positive and negative predictive values were calculated to determine whether early improvement predicted endpoint (week 3) response or remission. The study was conducted from July 2001 through June 2002. RESULTS: Among 234 @entity1 with >=  25% reduction in YMRS total score at week one, 167 (71.4%) responded and 121 (51.7%) remitted at endpoint. Of the 40 @entity1 with < 25% improvement, 25% (n = 10) responded and 5% (n = 2) remitted at endpoint. A total of 157 @entity1 had a >=  50% reduction in week 1 YMRS total score, of whom 132 (84.1%) responded and 101 (64.3%) remitted at endpoint. Of the 117 @entity1 with < 50% improvement, 45 (38.5%) responded and 22 (18.8%) remitted at endpoint. CONCLUSIONS: Improvement in @entity162 or mixed symptoms at week 1 appears to be a good predictor of treatment outcome. @entity1 not having sufficient improvement (< 25% reduction in YMRS score) were less likely to reach response or remission by week 3. @entity1 who achieved response by week 1 (>=  50% reduction in YMRS score) were likely to remain responders at endpoint. These data suggest the potential to assess benefit in the treatment of @entity162 or mixed symptoms within 1 week of initiating @entity1037 or @entity1090 .
